



5th September, 2016

## **Gastroenterology Clinical Trials – Crohn’s and Ulcerative Colitis**

Ballarat Health Services along with Dr Mohammed Al-Ansari, Gastroenterologist, are conducting a number of clinical research studies for patients with moderate to severely active Crohn’s disease or Ulcerative Colitis.

- **MONGERSEN (GED-0301)** - To investigate Mongersen for the treatment of patients with active Crohn’s disease.
- **REDHILL RHB 104-01** – To investigate and evaluate the efficacy and safety of RHB-104 which consists of 3 antibiotics in patients with Crohn’s disease.
- **TAKEDA VISIBLE 3031** – To investigate the effectiveness of Vedolizumab in patients with moderate to severely active Crohn’s disease.
- **TAKEDA VARSITY 3026** – To investigate the effectiveness of Vedolizumab compare to Adalimumab in patients with moderate to severely active Ulcerative Colitis.

**In order to participate patients must be:**

- **18 to 80 years old**
- **Diagnosed with Crohn’s Disease or Ulcerative Colitis for six months**

All study-related care is provided at no charge to the patient, including doctor visits, laboratory tests and procedures, and study medication.

If you have patients who you think may want to participate in this study, you are welcome to contact the **Clinical Research Department at Ballarat Health Services on 5320 4735** to obtain more information. We hope that you will consider referring patients for study evaluation. For further information please do not hesitate to contact me on 5320 8517.

Yours sincerely

**Angela Sandford**

**Ballarat Health Services**

**Gastroenterology Clinical Trials Coordinator**

**P: 53208517 E: [angela.sandford@bhs.org.au](mailto:angela.sandford@bhs.org.au)**